205 related articles for article (PubMed ID: 24966587)
81. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
82. Successful treatment of hepatitis B virus infection and related cryoglobulinaemic purpura with nucleoside/nucleotide analogues.
D'Amico E; Pace-Palitti V; Di Lembo E; Palazzi C
Clin Exp Rheumatol; 2013; 31(1):155. PubMed ID: 23190931
[No Abstract] [Full Text] [Related]
83. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
84. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
85. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
[TBL] [Abstract][Full Text] [Related]
86. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
87. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
88. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Lin Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
[No Abstract] [Full Text] [Related]
89. Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Shen Y; Jia Y; Zhou J; Ji J; Xun P
Clin Drug Investig; 2019 Sep; 39(9):835-846. PubMed ID: 31228017
[TBL] [Abstract][Full Text] [Related]
90. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.
Schildgen O; Hartmann H; Gerlich WH
Scand J Gastroenterol; 2006 Feb; 41(2):245-6. PubMed ID: 16484132
[No Abstract] [Full Text] [Related]
91. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Yuan G; Hu C; Zhou Y; Liu J; Huang H; Li Y; Yang D; Zhou F; Zhang YY; Zhou Y
Br J Clin Pharmacol; 2017 Oct; 83(10):2259-2265. PubMed ID: 28511283
[TBL] [Abstract][Full Text] [Related]
92. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
93. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
94. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Karatayli E; Idilman R; Karatayli SC; Cevik E; Yakut M; Seven G; Kabaçam G; Bozdayi AM; Yurdaydin C
Antivir Ther; 2013; 18(1):77-85. PubMed ID: 22878399
[TBL] [Abstract][Full Text] [Related]
95. Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis.
Dogan Z; Filik L; Ergül B; Sarikaya M
Saudi J Gastroenterol; 2015; 21(6):396-9. PubMed ID: 26655136
[TBL] [Abstract][Full Text] [Related]
96. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
[TBL] [Abstract][Full Text] [Related]
97. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
98. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
[TBL] [Abstract][Full Text] [Related]
99. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
100. Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Park JW; Yoo JJ; Kim SG; Kim YS
Hepatol Int; 2024 Apr; 18(2):700-701. PubMed ID: 38424394
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]